NASDAQ:NXL Nexalin Technology Q2 2026 Earnings Report $0.33 +0.00 (+0.45%) As of 08/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Nexalin Technology EPS ResultsActual EPSN/AConsensus EPS -$0.10Beat/MissN/AOne Year Ago EPSN/ANexalin Technology Revenue ResultsActual RevenueN/AExpected Revenue$0.09 millionBeat/MissN/AYoY Revenue GrowthN/ANexalin Technology Announcement DetailsQuarterQ2 2026Date9/2/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Nexalin Technology Earnings HeadlinesNexalin Technology Raises Liquidity via Short-Term NoteAugust 21 at 6:10 PM | tipranks.comNexalin Announces Capital Raise and Flexible Equity FacilityAugust 20 at 6:11 PM | tipranks.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 23 at 1:00 AM | Porter & Company (Ad)Nexalin Faces New Nasdaq Equity Deficiency, Delisting RiskAugust 17, 2026 | tipranks.comNexalin Expands and Extends Houston Headquarters Lease CommitmentJuly 29, 2026 | tipranks.comNexalin Appeals Nasdaq Delisting Following Compliance ShortfallsJuly 27, 2026 | tipranks.comSee More Nexalin Technology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email. Email Address About Nexalin TechnologyNexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation. The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions. Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.View Nexalin Technology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/17 - 08/21Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t OverRoss Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss3 Stocks Came Roaring Back—Now They’re Flashing Warning SignsMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
